191 related articles for article (PubMed ID: 34448427)
1. A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis.
Palladini G; Celant S; Milani P; Summa V; Affronti G; Olimpieri PP; Petraglia S; Foli A; Nuvolone M; Merlini G; Russo P;
Leuk Lymphoma; 2022 Jan; 63(1):205-211. PubMed ID: 34448427
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
Brennan X; Withers B; Jabbour A; Milliken S; Kotlyar E; Fay K; Ma D; Muthiah K; Hamad N; Dodds A; Bart N; Keogh A; Hayward C; Macdonald P; Moore J
Intern Med J; 2022 Oct; 52(10):1826-1830. PubMed ID: 36266066
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
[TBL] [Abstract][Full Text] [Related]
8. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Kastritis E; Dialoupi I; Gavriatopoulou M; Roussou M; Kanellias N; Fotiou D; Ntanasis-Stathopoulos I; Papadopoulou E; Ziogas DC; Stamatelopoulos K; Manios E; Ntalianis A; Eleutherakis-Papaiakovou E; Papanikolaou A; Migkou M; Papanota AM; Gakiopoulou H; Psimenou E; Tselegkidi MI; Tsitsilonis O; Kostopoulos I; Terpos E; Dimopoulos MA
Blood Adv; 2019 Oct; 3(20):3002-3009. PubMed ID: 31648323
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
Huang X; Wang Q; Chen W; Ren G; Liu Z
Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
Kastritis E; Leleu X; Arnulf B; Zamagni E; Cibeira MT; Kwok F; Mollee P; Hájek R; Moreau P; Jaccard A; Schönland SO; Filshie R; Nicolas-Virelizier E; Augustson B; Mateos MV; Wechalekar A; Hachulla E; Milani P; Dimopoulos MA; Fermand JP; Foli A; Gavriatopoulou M; Klersy C; Palumbo A; Sonneveld P; Johnsen HE; Merlini G; Palladini G
J Clin Oncol; 2020 Oct; 38(28):3252-3260. PubMed ID: 32730181
[TBL] [Abstract][Full Text] [Related]
11. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.
Palladini G; Sachchithanantham S; Milani P; Gillmore J; Foli A; Lachmann H; Basset M; Hawkins P; Merlini G; Wechalekar AD
Blood; 2015 Jul; 126(5):612-5. PubMed ID: 25987656
[TBL] [Abstract][Full Text] [Related]
12. Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary.
Lewis E; McCulloch S; Mahe E; Bahlis N; Neri P; Tay J; Duggan P; Jimenez-Zepeda VH
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e331-e334. PubMed ID: 37532664
[No Abstract] [Full Text] [Related]
13. Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.
Shimazaki C; Fuchida S; Suzuki K; Ishida T; Imai H; Sawamura M; Takamatsu H; Abe M; Miyamoto T; Hata H; Yamada M; Ando Y
Int J Hematol; 2016 Jan; 103(1):79-85. PubMed ID: 26588925
[TBL] [Abstract][Full Text] [Related]
14. Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience.
Riva M; Berno T; Cipriani A; Altinier S; Fedrigo M; Noventa F; Adami F
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e970-e974. PubMed ID: 34489209
[TBL] [Abstract][Full Text] [Related]
15. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.
Shen KN; Miao HL; Zhang CL; Feng J; Zhang L; Cao XX; Zhou DB; Wei S; Li J
Leuk Lymphoma; 2021 Apr; 62(4):874-882. PubMed ID: 33215569
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Jaccard A; Comenzo RL; Hari P; Hawkins PN; Roussel M; Morel P; Macro M; Pellegrin JL; Lazaro E; Mohty D; Mercie P; Decaux O; Gillmore J; Lavergne D; Bridoux F; Wechalekar AD; Venner CP
Haematologica; 2014 Sep; 99(9):1479-85. PubMed ID: 24859879
[TBL] [Abstract][Full Text] [Related]
17. [Treatment strategy for immunoglobulin light chain amyloidosis].
Fuchida SI
Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
[TBL] [Abstract][Full Text] [Related]
18. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.
Palladini G; Milani P; Foli A; Obici L; Lavatelli F; Nuvolone M; Caccialanza R; Perlini S; Merlini G
Haematologica; 2014 Apr; 99(4):743-50. PubMed ID: 24213149
[TBL] [Abstract][Full Text] [Related]
19. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
Manwani R; Cohen O; Sharpley F; Mahmood S; Sachchithanantham S; Foard D; Lachmann HJ; Quarta C; Fontana M; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
Blood; 2019 Dec; 134(25):2271-2280. PubMed ID: 31578202
[TBL] [Abstract][Full Text] [Related]
20. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V
Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
